Literature DB >> 2987740

Effects of opiates on urine output in the water-loaded rat and reversal by beta-funaltrexamine.

M Skingle, A G Hayes, M B Tyers.   

Abstract

The effects of several mu and kappa opioid receptor agonists on urinary excretion were examined in the water-loaded rat. Mu agonists induced anti-diuresis whereas kappa agonists caused diuresis. Furthermore, high efficacy kappa agonists eg. U50, 488H and tifluadom, produced marked diuretic effects, whereas kappa partial agonists eg. nalorphine, produced low maximum diuresis. Compounds having activity at both mu and kappa receptors eg. ethylketocyclazocine(EKC) and MR2034, produced a biphasic effect, an initial anti-diuretic effect followed by a more sustained diuretic effect. The irreversible mu receptor antagonist, beta-funaltrexamine (beta-FNA) antagonized the anti-diuretic effects elicited by fentanyl, pentazocine and buprenorphine and the initial anti-diuretic effect induced by EKC but did not inhibit the diuretic effects induced by U50, 488H and EKC. Thus, the use of beta-FNA in the water-loaded rat provides us with a valuable in vivo test which differentiates both mixed and selective opioid receptor agonists.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2987740     DOI: 10.1016/0143-4179(85)90047-2

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  3 in total

1.  Pharmacological profile of PD 117302, a selective kappa-opioid agonist.

Authors:  G E Leighton; M A Johnson; K G Meecham; R G Hill; J Hughes
Journal:  Br J Pharmacol       Date:  1987-12       Impact factor: 8.739

2.  Differential sensitivity of models of antinociception in the rat, mouse and guinea-pig to mu- and kappa-opioid receptor agonists.

Authors:  A G Hayes; M J Sheehan; M B Tyers
Journal:  Br J Pharmacol       Date:  1987-08       Impact factor: 8.739

3.  Reversal by beta-funaltrexamine of the antinociceptive effect of opioid agonists in the rat.

Authors:  A G Hayes; M Skingle; M B Tyers
Journal:  Br J Pharmacol       Date:  1986-08       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.